Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014.

about

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014.

Item

http://www.wikidata.org/entity/Q53832210

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Healthcare Cost Development in ...... Observational Study 2006-2014.

@en

Healthcare Cost Development in ...... Observational Study 2006-2014.

@nl

type

Item

label

Healthcare Cost Development in ...... Observational Study 2006-2014.

@en

Healthcare Cost Development in ...... Observational Study 2006-2014.

@nl

prefLabel

Healthcare Cost Development in ...... Observational Study 2006-2014.

@en

Healthcare Cost Development in ...... Observational Study 2006-2014.

@nl

P1476

Healthcare Cost Development in ...... Observational Study 2006-2014.

@en

P2093

David Nathanson

http://www.w3.org/2001/XMLSchema#string

Jan W Eriksson

http://www.w3.org/2001/XMLSchema#string

Johan Bodegård

http://www.w3.org/2001/XMLSchema#string

Thomas Nyström

http://www.w3.org/2001/XMLSchema#string

Ugne Sabale

http://www.w3.org/2001/XMLSchema#string

Urban Olsson

http://www.w3.org/2001/XMLSchema#string

P2860

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

The Economic Costs of Type 2 Diabetes: A Global Systematic Review

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.

Population-level effects of the national diabetes prevention programme (FIN-D2D) on the body weight, the waist circumference, and the prevalence of obesity.

Costs of remote monitoring vs. ambulatory follow-ups of implanted cardioverter defibrillators in the randomized ECOST study.

Medical care and payment for diabetes in China: enormous threat and great opportunity.

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

P2888

s41669-017-0063-y

P304

393-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S41669-017-0063-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Norhammar

P577

2018-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29623637

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

6249189

http://www.w3.org/2001/XMLSchema#string